RayzeBio, Inc. Common Stock
RYZB · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $61 | $34 | $6 |
| G&A Expenses | $11 | $6 | $1 |
| SG&A Expenses | $11 | $6 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $72 | $39 | $7 |
| Operating Income | -$72 | -$39 | -$7 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $4 | $10 | $0 |
| Pre-Tax Income | -$69 | -$29 | -$7 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$69 | -$29 | -$7 |
| % Margin | – | – | – |
| EPS | -1.75 | -0.73 | -0.17 |
| % Growth | -139.7% | -329.4% | – |
| EPS Diluted | -1.75 | -0.73 | -0.17 |
| Weighted Avg Shares Out | 39 | 40 | 40 |
| Weighted Avg Shares Out Dil | 39 | 40 | 40 |
| Supplemental Information | – | – | – |
| Interest Income | $4 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $0 | $0 |
| EBITDA | -$71 | -$39 | -$7 |
| % Margin | – | – | – |